+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Klebsiella pneumoniae Infections - Pipeline Review, H1 2020

  • ID: 5024738
  • Drug Pipelines
  • April 2020
  • Region: Global
  • 128 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • ABAC Therapeutics SA
  • Appili Therapeutics Inc
  • Eligochem Ltd
  • Melinta Therapeutics Inc
  • Oryn Therapeutics
  • RemAb Therapeutics SL
  • MORE
Klebsiella pneumoniae Infections - Pipeline Review, H1 2020

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Klebsiella pneumoniae Infections - Pipeline Review, H1 2020, provides an overview of the Klebsiella pneumoniae Infections (Infectious Disease) pipeline landscape.

Klebsiella pneumoniae is a Gram-negative bacteria. A Klebsiella pneumoniae infection is caused when the organism is able to enter the lungs. A Klebsiella pneumoniae infection is very common in patients with underlying diseases like diabetes, chronic lung diseases and chronic alcoholics. It is mostly a nosocomial infection that occurs in hospitalized patients with weakened immune system. Symptoms include necrosis, inflammation, hemorrhage, chills, dizziness, high fever, head ache and chest pain. Treatment includes antibiotics and hygiene lifestyle.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Klebsiella pneumoniae Infections - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Klebsiella pneumoniae Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Klebsiella pneumoniae Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Klebsiella pneumoniae Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Preclinical and Discovery stages are 1, 27 and 12 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 6 and 2 molecules, respectively.

Klebsiella pneumoniae Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Klebsiella pneumoniae Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Klebsiella pneumoniae Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Klebsiella pneumoniae Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Klebsiella pneumoniae Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Klebsiella pneumoniae Infections (Infectious Disease)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Klebsiella pneumoniae Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Klebsiella pneumoniae Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • ABAC Therapeutics SA
  • Appili Therapeutics Inc
  • Eligochem Ltd
  • Melinta Therapeutics Inc
  • Oryn Therapeutics
  • RemAb Therapeutics SL
  • MORE
  • Introduction
  • Klebsiella pneumoniae Infections - Overview
  • Klebsiella pneumoniae Infections - Therapeutics Development
  • Klebsiella pneumoniae Infections - Therapeutics Assessment
  • Klebsiella pneumoniae Infections - Companies Involved in Therapeutics Development
  • Klebsiella pneumoniae Infections - Drug Profiles
  • Klebsiella pneumoniae Infections - Dormant Projects
  • Klebsiella pneumoniae Infections - Discontinued Products
  • Klebsiella pneumoniae Infections - Product Development Milestones
  • Appendix
List of Tables
  • Number of Products under Development for Klebsiella pneumoniae Infections, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Klebsiella pneumoniae Infections - Pipeline by ABAC Therapeutics SA, H1 2020
  • Klebsiella pneumoniae Infections - Pipeline by Acies Bio doo, H1 2020
  • Klebsiella pneumoniae Infections - Pipeline by AEON Medix Inc, H1 2020
  • Klebsiella pneumoniae Infections - Pipeline by Affinivax Inc, H1 2020
  • Klebsiella pneumoniae Infections - Pipeline by Akthelia Pharmaceuticals Ltd, H1 2020
  • Klebsiella pneumoniae Infections - Pipeline by Appili Therapeutics Inc, H1 2020
  • Klebsiella pneumoniae Infections - Pipeline by Armata Pharmaceuticals Inc, H1 2020
  • Klebsiella pneumoniae Infections - Pipeline by BB200 LLC, H1 2020
  • Klebsiella pneumoniae Infections - Pipeline by Bugworks Research India Pvt Ltd, H1 2020
  • Klebsiella pneumoniae Infections - Pipeline by Celdara Medical LLC, H1 2020
  • Klebsiella pneumoniae Infections - Pipeline by ContraFect Corp, H1 2020
  • Klebsiella pneumoniae Infections - Pipeline by Debiopharm International SA, H1 2020
  • Klebsiella pneumoniae Infections - Pipeline by Eligochem Ltd, H1 2020
  • Klebsiella pneumoniae Infections - Pipeline by EnBiotix Inc, H1 2020
  • Klebsiella pneumoniae Infections - Pipeline by F. Hoffmann-La Roche Ltd, H1 2020
  • Klebsiella pneumoniae Infections - Pipeline by Fedora Pharmaceuticals Inc, H1 2020
  • Klebsiella pneumoniae Infections - Pipeline by Forge Therapeutics Inc, H1 2020
  • Klebsiella pneumoniae Infections - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2020
  • Klebsiella pneumoniae Infections - Pipeline by Melinta Therapeutics Inc, H1 2020
  • Klebsiella pneumoniae Infections - Pipeline by Microbiotix Inc, H1 2020
  • Klebsiella pneumoniae Infections - Pipeline by Neoculi Pty Ltd, H1 2020
  • Klebsiella pneumoniae Infections - Pipeline by Nosopharm SAS, H1 2020
  • Klebsiella pneumoniae Infections - Pipeline by Oryn Therapeutics, H1 2020
  • Klebsiella pneumoniae Infections - Pipeline by Peptilogics Inc, H1 2020
  • Klebsiella pneumoniae Infections - Pipeline by Phico Therapeutics Ltd, H1 2020
  • Klebsiella pneumoniae Infections - Pipeline by ReAlta Life Sciences Inc, H1 2020
  • Klebsiella pneumoniae Infections - Pipeline by RemAb Therapeutics SL, H1 2020
  • Klebsiella pneumoniae Infections - Pipeline by Shionogi & Co Ltd, H1 2020
  • Klebsiella pneumoniae Infections - Pipeline by Soligenix Inc, H1 2020
  • Klebsiella pneumoniae Infections - Pipeline by Spero Therapeutics Inc, H1 2020
  • Klebsiella pneumoniae Infections - Pipeline by Summit Therapeutics Plc, H1 2020
  • Klebsiella pneumoniae Infections - Pipeline by Syntiron LLC, H1 2020
  • Klebsiella pneumoniae Infections - Pipeline by VaxNewMO LLC, H1 2020
  • Klebsiella pneumoniae Infections - Pipeline by Vaxxilon AG, H1 2020
  • Klebsiella pneumoniae Infections - Pipeline by Venus Medicine Research Center, H1 2020
  • Klebsiella pneumoniae Infections - Dormant Projects, H1 2020
  • Klebsiella pneumoniae Infections - Dormant Projects, H1 2020 (Contd..1), H1 2020
  • Klebsiella pneumoniae Infections - Dormant Projects, H1 2020 (Contd..2), H1 2020
  • Klebsiella pneumoniae Infections - Discontinued Products, H1 2020
List of Figures
  • Number of Products under Development for Klebsiella pneumoniae Infections, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Top 10 Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • ABAC Therapeutics SA
  • Acies Bio doo
  • AEON Medix Inc
  • Affinivax Inc
  • Akthelia Pharmaceuticals Ltd
  • Appili Therapeutics Inc
  • Armata Pharmaceuticals Inc
  • BB200 LLC
  • Bugworks Research India Pvt Ltd
  • Celdara Medical LLC
  • ContraFect Corp
  • Debiopharm International SA
  • Eligochem Ltd
  • EnBiotix Inc
  • F. Hoffmann-La Roche Ltd
  • Fedora Pharmaceuticals Inc
  • Forge Therapeutics Inc
  • Kyorin Pharmaceutical Co Ltd
  • Melinta Therapeutics Inc
  • Microbiotix Inc
  • Neoculi Pty Ltd
  • Nosopharm SAS
  • Oryn Therapeutics
  • Peptilogics Inc
  • Phico Therapeutics Ltd
  • ReAlta Life Sciences Inc
  • RemAb Therapeutics SL
  • Shionogi & Co Ltd
  • Soligenix Inc
  • Spero Therapeutics Inc
  • Summit Therapeutics Plc
  • Syntiron LLC
  • VaxNewMO LLC
  • Vaxxilon AG
  • Venus Medicine Research Center
Note: Product cover images may vary from those shown
Adroll
adroll